Klinomics Launches Full-Scale Turnaround Through Xenocare Project

Clinomics announced on the 3rd that it will promote the Xenocare (Clinic, Application, Report, Engine) project, which combines the company's core infrastructure and business capabilities.

The Xenocare project is a project that precisely produces and analyzes large-scale genome data through the pre-established Xeno Engine infrastructure and provides Xenoreport, customized health functional foods (Application), and medical (Clinic) services using multi-omics and artificial intelligence (AI) technologies.

Clinomics is promoting the provision of personalized customized health functional foods optimized for individuals by utilizing Gageumnongsan and its subsidiary KoenF, which were recently acquired, as well as directly developing and selling health functional foods that help overcome aging and prevent cancer.

In addition, it aims to build a health information big data platform that integrates advanced multi-omics analysis including genome analysis technology with customers' medical information (EMR) and personal health information (PGHD) in connection with hospitals and clinics.

Through the platform, it plans to collaborate with partner institutions (universities and hospitals, research institutes, pharmaceutical companies, insurance companies, food companies, etc.) to develop therapeutic technologies (such as ADC), therapeutics and new drugs (applying glycoengineering), health functional foods, and other healthcare service products.

The medical technologies, pharmaceuticals, healthcare products, and services developed through the platform will be provided as optimized hyper-personalized customized healthcare services to customers, and the company will promote the completion of a platform that integrates the entire medical cycle from diagnosis and prediction to treatment, monitoring, anti-aging, and reverse aging.

Baek Seohyun, CEO of Clinomics, said, “To maximize sales, we recently established a Planning/Marketing New Business Division within the company,” and added, “Through the Xenocare project, we aim to achieve sales of over 20 billion KRW this year and turn around to a profitable company by achieving sales of over 50 billion KRW from 2025.”